LOAD MORE
You're viewed 36 of 64 products
Tenofovir
References
FAQ's
References
- Holy, Antonin; Dvorakova, Hana; Declercq, Erik Desire Alice; Balzarini, Jan Marie Rene, Antiretroviral Enantiomeric Nucleotide Analogs, Gilead Sciences, Inc., Czech Republic, et al, EP654037B1, August 4, 1993
- Holy, Antonin; Masojidkova, Milena, Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. I. The stepwise approach, Collection of Czechoslovak Chemical Communications, Volume: 60, Issue: 7, Pages: 1196-212, 1995
- Jullien, Vincent; Treluyer, Jean-Marc; Pons, Gerard; Rey, Elisabeth, Determination of Tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,Volume: 785, Issue: 2, Pages: 377-381, 2003
Frequently Asked Questions
What are the impurities typically found in Tenofovir?
The impurities typically found in Tenofovir include related substances, such as process-related impurities and degradation products.
How are Tenofovir impurities analyzed?
The impurities in Tenofovir are analyzed using high-performance liquid chromatography (HPLC), which separates the impurities from the drug substance and quantifies their concentrations.
How can Tenofovir impurities be removed?
The impurities in Tenofovir are removed, through various purification methods, such as crystallization and column chromatography. The extent to which the removal of impurities depends on their chemical properties and concentration.
What are the temperature conditions required to store Tenofovir impurities?
Tenofovir impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.
